Coya Therapeutics, Inc. ( (COYA) ) just unveiled an update.
Coya Therapeutics, a clinical-stage biotech firm, reported positive outcomes from a study on Alzheimer’s and detailed its strategic plans, including advancing its pipeline for neurodegenerative diseases like ALS and Parkinson’s. With a focus on enhancing regulatory T cell function to tackle neuroinflammation, Coya sees 2025 as pivotal, expecting significant clinical data releases and potential partnerships. The company, which raised capital to support its goals, continues to innovate with its lead product, COYA 302, a combination biologic targeting neurodegenerative conditions.
See more data about COYA stock on TipRanks’ Stock Analysis page.
